Nearly 4,500 cases were pulled from shelves in 23 states after it was found that the affected cans had been mislabeled.

Dupilumab and omalizumab are both effective adjuvant treatments for adults with bullous pemphigoid, though dupilumab may provide better outcomes.

Allergic and/or T2 inflammatory biomarkers are more common in patients with asthma or asthma-COPD overlap vs in patients with COPD alone.